#LoMásLeído La jumillana Bodegas Juan Gil ficha a Interpath para explorar la entrada de un inversor externo murciaplaza.com/murciaplaza/…
64
La firma jumillana Bodegas Juan Gil ficha a Interpath para explorar la entrada de un inversor externo murciaplaza.com/murciaplaza/…
97
Conseil : Interpath recrute chez les Big Four pour monter en puissance trib.al/5gEtWf4
1,492
Jun 15
La jumillana Bodegas Juan Gil ficha a Interpath para explorar la entrada de un inversor externo
murciaplaza.com/murciaplaza/…
91
Jun 15
La jumillana Bodegas Juan Gil ficha a Interpath para explorar la entrada de un inversor externo murciaplaza.com/murciaplaza/…
81
Jun 12
Ken Fennell to retire from Interpath Ireland after 34-year career businesspost.ie/companies/ke…
1,039
Jun 9
📊 Au sommaire de SMART CAPITAL ce mercredi 10 juin avec @adumourier et ses invités :
▪ 𝗘𝘅𝗽𝗲𝗿𝘁𝘀-𝗰𝗼𝗺𝗽𝘁𝗮𝗯𝗹𝗲𝘀 : 𝗾𝘂𝗲𝗹𝗹𝗲 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 ?
Avec @Alienor_M, présidente, @Margie
▪ 𝗖𝗮𝗯𝗶𝗻𝗲𝘁𝘀 : 𝗿𝗲́𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝗼𝘂 𝗿𝘂𝗽𝘁𝘂𝗿𝗲 ?
Avec Vania Mermoud, Managing Director Transaction Services, Interpath et Erwan Lirin, président, BM&A
▪ 𝗟𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁 𝗱'𝘂𝗻 𝗰𝗮𝗯𝗶𝗻𝗲𝘁 : 𝗰𝗲 𝗾𝘂'𝗶𝗹 𝗳𝗮𝘂𝘁 𝘀𝗮𝘃𝗼𝗶𝗿
Avec Saïda Sehrine, fondatrice, SAADA AUDIT & CONSEIL
#smartcapital, rendez-vous ce mercredi 10 juin à 7h30 sur @B_SMART_TV
1
1
162
Exclusive: JD Sports Fashion is working with advisers at Interpath to sell the brand licence it owns for Billionaire Boys Club, the streetwear label founded by musician Pharrell Williams. news.sky.com/story/mark-klei…
4
7,847
#ASCO26 | Abstr 9500
5y FU from KN942: Individualized neoantigen therapy intismeran pembro vs pembro in resected melanoma
Ph3 INTerpath-001 study is fully enrolled.
@ASCO @OncoAlert
4
12
1,248
Three corrections, one clarification.
Clarification on “running.” “Running” means operationally ready, not active commercial production. The stronghold is built, licensed, staffed, and supplied. The infrastructure is running in the sense that a power plant is running before the grid draws load. The trigger event is the MHRA MAA decision; commercial output activates at that inflection.
One. mRNA vaccines do not store at sub-150°C. Pfizer-BioNTech is -70°C; Moderna is -20°C. Sub-150°C is the liquid nitrogen cryogenic range used for living-cell preservation only. The fingerprint specifically requires living-cell modality. You conflated cold storage with cryogenic storage; they are not the same specification.
Two. WP50’s non-attribution is anomalous against Merck’s own pattern, not against generic pharma norms. Wilmington is named for Keytruda biologics. Durham is named for vaccines. De Soto is named for Animal Health. The May 10, 2026 Oncology Business Unit restructuring formally designated Keytruda biologics to Wilmington, explicitly removing Keytruda from any WP50 attribution. When Merck names a facility’s purpose, Merck names it. WP50 does not get named.
Three. INTerpath-007 is not “one terminated Phase 2.” It is one entry in a six-trial pattern that maps onto the spectrum of endogenous DC competence. Melanoma (preserved DCs): Phase 3 at INTerpath-001. NSCLC (intermediate): Phase 3 at -002 and -009. Renal cell and urothelial (intermediate): stuck at Phase 2 signal-finding. Cutaneous SCC (heavily silenced): terminated. KEYNOTE-630 had already falsified pembrolizumab monotherapy in the same indication before -007 was tested. Two empirical falsifications, same indication, same silenced instruction layer. That is not routine portfolio management.
Four. The three April 2026 events are not “three unrelated events within 30 days.” They sit inside a documented eighteen-month staging sequence with twelve discrete operational events compressed into the final nine months: August 27, 2025 Advent BioServices acquisition announcement; September 3, 2025 FDA AMT designation to Ori; October 24, 2025 Advent closing under wholly-owned NWBio control; November 20, 2025 Grade C suite construction at Sawston; December 30, 2025 share authorization expansion Certificate of Amendment effective in Delaware; March 5, 2026 Rare Cancers Act Royal Assent; March 17, 2026 MHRA-NICE Aligned Pathway announcement; April 1 Aligned Pathway operational; April 22 MHRA action on UK MIA 54923; April 30 Jenkins NWBio appointment. Each event independently documented in primary sources.
Structural pattern recognition presented as such is inferential synthesis, not speculation dressed as fact. The metaphor is the rhetorical layer. The structural argument is the empirical layer beneath it.
1
2
81
$nwbo @alphavestcap
"The assertion is a confident conclusion drawn from weak circumstantial premises, presented as if the inferential leap has already been validated. It hasn't. The underlying thesis may eventually prove correct, but as stated it is speculative dressed as fact — which is precisely the kind of framing that misleads retail investors in small-cap biotech.'
x.com/andrewcaravello/status…
WP50 isn’t a vaccine plant.@andrewcaravello
$NWBO #DCVax ❄️
$MRK
#Winterfell, the Long Night, and the Failed Trials
🏰 The Stronghold
Winterfell is the code name. WP50 is the building. Merck's three-floor facility at West Point, Pennsylvania, occupied early 2024, with sub-150°C cryogenic staging at the foundation, lyophilpasted"Merck’s WP50 isn’t a vaccine plant. It’s a precision deployment hub for [#DCVax](x.com/hashtag/DCVax?src=hash…), staging custom immunotherapy kits built on $NWBO’s immune logic. With cryo infrastructure, Flaskworks automation, and UK legal backing (SI 87), it’s not theory anymore — it’s running."2:53 PMClaude responded: This post makes a number of bold, confident claims that go well beyond what the evidence actually supports.This post makes a number of bold, confident claims that go well beyond what the evidence actually supports. Let me walk through the key issues.
What the post actually establishes vs. what it claims
The document describes a Merck facility (WP50) at West Point, PA with sub-150°C cryogenic storage and lyophilization capabilities, a postdoctoral hire with dendritic cell expertise, and the INTerpath trial portfolio for V940. From these facts, the author builds an elaborate thesis that Merck is secretly preparing to manufacture NWBio's DCVax platform.
The logical gaps are substantial
The cryogenic infrastructure argument proves too much. Sub-150°C storage is standard for mRNA vaccines, cell therapies of many kinds, and biological samples generally. The author interprets "no public program attribution" for WP50 as suspicious silence — but most pharma facility buildouts don't receive press releases.
The INTerpath-007 termination is treated as falsification of the entire mRNA vaccine approach, but a single terminated Phase 2 in one indication is routine portfolio management, not platform collapse. The Phase 3 trials in melanoma and NSCLC are still running.
The Jenkins appointment, the MHRA action, and the postdoc hire are presented as a "convergence" — but three unrelated events within 30 days is pattern-matching, not evidence of coordination.
The "Flaskworks automation" and "SI 87" claims in your summary aren't in the document at all, which raises the question of where those are coming from.
The core problem is that this is a highly sophisticated investment thesis dressed in Game of Thrones metaphor, built on circumstantial infrastructure observations, and written in a style designed to feel like revealed truth. That rhetorical confidence isn't the same as evidence of a partnership that hasn't been announced.
What's your actual question about this material?You said: one twitter poster has alleged:"Merck’s WP50 isn’t a vaccine plant.one twitter poster has alleged:"Merck’s WP50 isn’t a vaccine plant. It’s a precision deployment hub for [#DCVax](x.com/hashtag/DCVax?src=hash…), staging custom immunotherapy kits built on $NWBO’s immune logic. With cryo infrastructure, Flaskworks automation, and UK legal backing (SI 87), it’s not theory anymore — it’s running." is this assertion logical?2:55 PMClaude responded: No, it isn't logical — at least not as stated.No, it isn't logical — at least not as stated. Here's why.
The claim outpaces the evidence at every step
"It's not theory anymore — it's running" is a definitive operational claim. But nothing in the public record confirms that WP50 is manufacturing or staging DCVax product. The evidence cited is entirely infrastructural and circumstantial: a facility with cryogenic storage exists, a relevant postdoc was hired, some patents overlap. None of that confirms an active DCVax operation.
The specific elements don't hold up well
"Flaskworks automation" — Flaskworks makes automated cell culture systems used broadly across cell therapy. The presence of such equipment at a Merck facility would not be specific to DCVax; dozens of cell therapy programs use the same platform.
"SI 87" (likely referring to UK Statutory Instrument 87) — this is a regulatory instrument related to cell therapy manufacturing licensing in the UK. Citing it as "legal backing" for a specific Merck-NWBio operation conflates general regulatory framework with program-specific authorization.
"Cryo infrastructure" — as noted before, this is standard for mRNA, gene therapy, and numerous cell therapy programs. It is not a DCVax fingerprint.
The rhetorical structure is the tell
The phrase "it's not theory anymore" is doing enormous work without delivering the evidence that would justify it. A genuine operational confirmation would come from an SEC filing, a partnership announcement, a clinical trial registration, or a regulatory submission — not from inferring purpose from facility architecture.
The bottom line
The assertion is a confident conclusion drawn from weak circumstantial premises, presented as if the inferential leap has already been validated. It hasn't. The underlying thesis may eventually prove correct, but as stated it is speculative dressed as fact — which is precisely the kind of framing that misleads retail investors in small-cap biotech.
23 Jul 2025
🧬 How $MRK WP50 Became the Hidden Deployment Hub for $NWBO Programmable Immune System
What began as a “vaccine plant” is now the staging ground for modular, patient-specific immunotherapy kits, built to deploy, not mass-produce.
⏱️ Estimated Read Time: 24-28 minutes
🏗️ The Facility That Quietly Changed Everything
In early 2021, as global headlines focused on mRNA, Merck quietly broke ground on a project that had nothing to do with COVID, flu, or Gardasil. The filing called it “Building 50” — WP50 in internal terms — and labeled it a “vaccine and office” expansion at the company’s massive West Point campus in Pennsylvania.
But behind that generic description was a $120 million facility unlike anything else in Merck’s vaccine empire.
WP50 wasn’t designed for bulk manufacturing. It was built for precision staging — specifically, for modular immunotherapy kits. No batch fermenters. No large-volume bioreactors. And critically, no design elements to support high-throughput conjugate vaccine production, like what Merck uses for Prevnar or MMR.
Even its legal footprint gave it away. WP50 received a stormwater discharge exemption — a regulatory carve-out typically reserved for low-effluent, cleanroom-intensive sites like biologic dispatch facilities. Its projected wastewater output was just 3,500 gallons a day. That’s less than a commercial laundromat.
Why would Merck invest that much into a facility that doesn’t produce at scale?
Because it wasn’t built to output product.
It was built to input logic.
🔬 A Facility Built for a Therapeutic Reboot
The timing was no coincidence.
In 2021, three key developments redefined the landscape of personalized immunotherapy:
•DCVax-L had just published its long-awaited glioblastoma survival results in JAMA Oncology
•DCVax-Direct completed Phase I, showing measurable tumor regression across multiple solid tumors with direct injection
•Mayo Clinic had begun releasing trial data showing that traditional conjugate vaccines like Prevnar and Pneumovax could enhance dendritic cell therapy when injected into tumors
Simultaneously, Northwest Biotherapeutics (NWBO) acquired Flaskworks — a Boston startup developing fully automated dendritic cell manufacturing hardware — and licensed IP from Roswell Park covering microbial adjuvants and DC maturation.
In short:
The architecture for a logic-coded immune platform had emerged.
And WP50 looked built to support it.
Its layout — sterile fill rooms, cryogenic bays, and modular cleanroom segmentation — points to one thing: a real-time immunotherapy staging facility, not a traditional vaccine plant.
This is where the immune code gets deployed.
❄️ Cryo as a Design Principle — Not a Feature
Most vaccine plants operate with refrigeration between 2°C and 8°C. Even mRNA requires only −80°C at most. WP50 was designed for sub–150°C cryogenic staging — the range needed for autologous cell therapies like DCVax.
That kind of deep freeze isn’t a convenience.
It’s a commitment.
It means the facility is architected to handle living cell products that must stay frozen from the moment of manufacture to the moment of injection — no room temperature hold, no thaw until delivery.
That matches:
•DCVax-L, cryopreserved and patient-specific
•Poly-ICLC, a lyophilized RNA mimic that benefits from cryogenic buffering pre-fill
•IFN-γ, DECOY20, and other Matrix-class boosters that require temperature integrity
This isn’t speculative. It’s architectural logic.
Merck didn’t just install cryo bays for flexibility.
They embedded them as a core design element — because the kit they were building wasn’t generic.
It was meant to be customized. And cold. And ready to run.
🧬 Not a Fill Plant — A Signal Router
On its second floor, WP50 houses modular cleanrooms configured not by product line, but by signal class — the logic-coded categories that correspond to booster types in the Bosch Matrix.
Each suite can be isolated by function, allowing WP50 to:
•Fill lyophilized viral mimics like Poly-ICLC (Class A)
•Prepare sterile liquid emulsions like G100 (Class B)
•Load recombinant cytokines like IFN-γ or IFN-α2 (Class I)
•Co-package pre-filled syringes like Prevnar (Class V), filled nearby at Merck’s Building 63A
•Pair killed microbial agents like DECOY20 (Class D) or depot-formulated adjuvants like R848 (Class C)
This isn’t a production line.
It’s a programmable stack execution node.
When Flaskworks manufactures a batch of DCVax for a patient, WP50 doesn’t just hold the vial. It fills or stages the corresponding immune boosters, labels the kit, and prepares it for personalized dispatch.
DCVax is the payload.
WP50 is the switchboard.
🏛️ B32 — The Vault That Buys Time
Every high-speed node needs a buffer. That’s where Merck’s Building 32 (B32) comes in — a dedicated −70°C storage facility integrated into the same West Point grid as WP50.
Its job isn’t to produce.
Its job is to pause.
If Flaskworks finishes manufacturing but regulatory clearance isn’t ready, B32 holds the cryopreserved vaccine vials. If Eden scripts a booster stack that requires coordination, B32 holds the partially assembled kit until pairing is complete. If a trial site needs rolling inventory — B32 stages, tracks, and preserves.
The layout includes:
•Walk-in cryogenic vaults
•Mobile ultra-cold units
•GMP-grade chain-of-custody logs
•Batch-linked barcode tracking
This isn’t warehouse storage.
It’s deployment buffering for a living therapy that can’t afford to degrade.
Together, WP50 and B32 form a two-node immune engine:
•One that executes.
•One that preserves.
🔁 SI 87 and CNPV: The Legal Rails That Activate the Grid
Even the most sophisticated system is useless without regulatory alignment. WP50 doesn’t operate in isolation. It sits squarely between two real-world legal frameworks that allow its logic-coded kits to move.
🇬🇧 SI 87 – UK Specials Law
•Allows named-patient use of unlicensed autologous cell therapies
•Supports pairing with GMP-grade boosters not yet centrally authorized
•Enables import/export of cryopreserved DCVax kits into the UK
•No marketing license required — just physician justification and GMP documentation
🇺🇸 CNPV – Commissioner’s National Priority Voucher (FDA)
•Enables 60–180 day review for therapies with completed Phase III trials
•Accepts patient-specific, real-world–ready formats
•Requires no new trial if safety/efficacy are proven — which they are for DCVax-L (via JAMA Oncology)
•Compatible with Flaskworks production and WP50 fill logic
This means Merck’s West Point stack is already regulatory-operable on both sides of the Atlantic.
In one mode, WP50 assembles and ships kits into the UK under SI 87.
In another, it stages and dispatches them domestically under CNPV clearance.
In both, it bypasses traditional drug launch infrastructure — and moves the immune system at patient speed.
🧬 From Tissue to Therapy: A Personalized Immune Stack in Motion
This isn’t drug delivery. It’s logic delivery.
Every DCVax kit begins not in a factory, but with a patient’s own biology — a tumor sample and a monocyte harvest via leukapheresis.
There are two therapeutic pathways:
•DCVax-L, used post-resection for tumors like glioblastoma
•DCVax-Direct, used for inoperable tumors, with intratumoral injection paired with localized immune stimulants
In either case, the journey starts with living input. Not inventory. Not a generic dose.
And what comes next is automated.
⚙️ Flaskworks — The Engine That Manufactures Immune Code
Flaskworks isn’t a CMO or a contract lab. It’s a closed-system, GMP-enabled hardware platform — built to produce dendritic cell vaccines without human hands.
At its core is Eden, the automated device architecture described in U.S. Patent 10,647,954. Here’s what it does:
•Uses disposable cartridges to isolate, mature, and antigen-load monocytes
•Guides the cells through cytokine programming (e.g., GM-CSF, IL-4)
•Pulses them with tumor lysate — personalized per patient
•Cryopreserves the final DCVax product into single-use, barcoded vials
It tracks flow rate, pressure, pH, and maturation timing in real time — all logged and traceable.
Flaskworks isn’t batch manufacturing.
It’s immune programming — scaled, sealed, and per patient.
🧠 Eden — The Logic That Decides What Comes Next
Once Flaskworks produces the cell-based payload, Eden, NWBO’s internal orchestration system, assigns the booster logic using the Bosch Matrix — a functional immune codebook.
For each patient, Eden determines:
•Which signal classes are needed (A B I, or B C D, etc.)
•Which cytokines or immune tones are ideal (e.g., IL-12p70, IFN-γ)
•Whether the vaccine will be injected systemically (DCVax-L) or intratumorally (DCVax-Direct)
•What delivery formats are appropriate (syringe, patch, depot gel, etc.)
Eden doesn’t generalize. It scripts.
Then WP50 executes — physically pairing Flaskworks-made DCVax vials with logic-matched immune stimulants, all under regulatory guardrails.
No two kits are the same.
Each is a custom-coded immune program — generated from biology, compiled by Eden, and staged by Merck.
🧪 The Bosch Matrix: Functional Immune Classes That Plug In Like Code
In 2025, Dr. Marnix Bosch publicly outlined a new way to classify immune stimulants — not by molecule, but by signal function. This framework, now known as the Bosch Matrix, divides immune boosters into modular, combinable classes:
•Class A: Viral Mimics
e.g., Poly-ICLC (Hiltonol) — lyophilized dsRNA that triggers TLR3, driving Type I interferons and IL-12p70 for systemic T-cell priming.
•Class B: Inflammatory Ignition (TLR4)
e.g., G100 — a nanoemulsion used intratumorally to induce APC recruitment and localized inflammation.
•Class C: TLR7/8 Modulators
e.g., R848, MEDI9197 — small molecules that fine-tune innate immune tone; may be formulated as depot injections or topical gels.
•Class D: Danger Signal Inducers
e.g., DECOY20 — killed microbial ligands that activate PRRs broadly, often used for intratumoral shock priming.
•Class I: Cytokine Amplifiers
e.g., IFN-γ or IFN-α2 — recombinant proteins used to restore signaling in low-responder or immunosuppressed patients.
•Class V: Recall Triggers
e.g., Prevnar, Pneumovax — pre-filled conjugate vaccines originally used for infectious disease, now reimagined to awaken myeloid memory in cancer.
Each class isn’t a brand. It’s a function.
Each agent isn’t just a drug. It’s a signal in a stack.
And WP50 was designed to physically execute every one.
🏭 WP50 Matches Format to Function
Each Matrix class has a specific physical format:
•Lyophilized (Class A, Class C)
•Cold-chain liquid (Class B, Class I)
•Sterile-filled microbial suspension (Class D)
•Pre-loaded syringe (Class V)
WP50’s layout aligns precisely:
•Lyophilization lines to prep Poly-ICLC and TLR7/8 agents
•Cold-fill bays for nanoemulsions and recombinant cytokines
•Cryo staging rooms for DCVax vials and Poly-ICLC intermediates
•Sterile prep suites for microbial adjuvants like DECOY20
•Labeling and co-packaging docks for Prevnar or Pneumovax syringes filled at B63/B63A
Each cleanroom suite can be dedicated to one signal class, ensuring sterility, format integrity, and per-class documentation.
That means WP50 can produce:
•A DCVax-L Poly-ICLC IFN-γ combo
•A DCVax-Direct G100 DECOY20 pairing
•Or a multi-stage DCVax-L regimen boosted over time with different Matrix agents
The building doesn’t run a pipeline.
It runs immune instructions, per patient.
💉 L vs. Direct: Route Matters — So Does Format
The booster logic isn’t just scientific. It’s spatial.
•DCVax-L is administered systemically, usually intradermally or subcutaneously, meaning boosters like IFN-γ or Poly-ICLC can be given separately, sometimes on offset schedules. Format flexibility is helpful but not always critical.
•DCVax-Direct, however, is injected into the tumor, often under image guidance. Boosters for Direct need to be:
•Pre-filled
•Timed precisely
•Co-localized with the injection
This makes sterile, syringe-ready boosters essential, especially for intratumoral agents like G100 or recall adjuvants like Prevnar.
That’s where Merck’s Building 63A completes the loop.
Its 70 million–dose annual capacity wasn’t built for DCVax itself.
It was built to stage the booster fuel — for programmable, injectable therapy kits.
In short:
•DCVax is the driver.
•The Bosch Matrix is the map.
•WP50 and 63A are the vehicles.
•And the destination is real-world immune control, on demand.
🌍 Kits Become Infrastructure: How the Immune OS Scales Without Rebuilding Pharma
In traditional biotech, scale means inventory — vials on shelves, pallets in warehouses, and global supply chains stretching across months.
But NWBO’s model scales differently.
Here, the therapy is logic-coded, and the supply chain is node-based:
•Flaskworks units produce immune payloads per patient
•Eden scripts booster combinations using Matrix logic
•WP50 stages and deploys kits per regulation
•And B32 or equivalent cryo storage buffers demand
To replicate the system, you don’t need a new factory.
You just need another node that speaks the same immune language.
🏗️ Flaskworks as the Hardware Platform, Eden as the Software Stack
Each Flaskworks unit is a sealed, GMP-certified immune factory:
•Small enough for hospital-based GMP suites
•Cleanroom-ready for CMO or academic installs
•Fully automated, running Eden’s logic scripts on disposable cartridges
And Eden doesn’t change across geographies.
It speaks the same Bosch Matrix logic, Class A through V, no matter where it’s installed.
That means:
•A patient in London can receive DCVax-L Poly-ICLC IFN-γ from a Flaskworks unit at Advent
•A patient in Chicago can receive DCVax-Direct G100 DECOY20 from a node built at a local health system
The inputs vary.
The platform doesn’t.
It’s scalable, transferable, and globally regulatory-aligned.
✅ It’s a franchise model, for personalized immunity.
🛠️ Final Assembly: Why Merck’s Infrastructure Quietly Completes the Immune Stack
The real story of WP50 isn’t about vaccine volume.
It’s about immune precision—and industrial enablement.
During COVID, Merck built WP50 and 63A to quietly house something the market hadn’t yet named:
a programmable immunotherapy distribution system, routed by biology, not batches.
Today, it connects:
• Flaskworks: the engine that makes personalized DCVax from patient tissue
• Eden: the logic compiler that assigns Bosch Matrix–class boosters
• WP50: the facility that assembles, matches, and packages each stack
• B32: the vault that buys time, preserving each kit until dispatch
• 63A: the syringe engine that fills, stages, and scales real-world delivery boosters
• SI 87 and UK Modular Manufacturing Law: the legal rails that now authorize decentralized, per-patient immunotherapy delivery
This is no longer theoretical.
As of July 23, 2025, the UK’s Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations 2025 is now in force—a world-first legal framework enabling personalized cell and gene therapies to be manufactured, assembled, and administered near the patient.
The law supports:
• On-site and mobile production
• Small-batch or single-patient dosing
• Cryogenic handoff and direct dispatch
• Regulatory control without re-approval
It is tailor-made for what WP50 already does.
And globally, regulators are catching up. The ICMRA’s international working group has now endorsed decentralized, point-of-care manufacturing as a viable and harmonizable pathway for advanced therapies, making WP50 not just a national asset, but a globally replicable immune infrastructure model.
“Highly personalised treatment—made for one person, in one place, at one time—becomes part of routine care,”
said MHRA Chief Executive Lawrence Tallon.
And this infrastructure isn’t operating in a vacuum.
While the U.S. has not yet enacted a formal decentralized framework, the CNPV (Commissioner’s National Priority Voucher) initiative shows signs of convergence, potentially offering expedited review for platforms like DCVax that already completed Phase III. If adopted, it would align the U.S. operationally with the UK’s legal breakthrough.
This system wasn’t built for Prevnar or Gardasil.
It was built for DCVax.
And it works with every Matrix-class booster, even those Merck doesn’t own, because the stack isn’t built around brands.
It’s built around immune function: signal mimics, TLR agonists, cytokine drivers, memory triggers.
What matters is not the molecule, but the message.
• Poly-ICLC? Check.
• DECOY20? Check.
• R848? G100? IFN-γ? Check, check, and check.
Merck owns the infrastructure.
NWBO owns the code.
And together, they’ve quietly constructed something no one else has:
a plug-and-play immune execution engine, now legally operable in the UK, and structurally ready for the U.S. the moment policy catches up.
They didn’t just build a therapy.
They built an operating system for live, logic-coded immunity.
It’s not theoretical.
It’s running.
And now, under law
It’s deployable.
It’s scalable.
It’s real. 🗽
$MRK $BMY $PFE $GILD $LLY $AZN $MRNA $VXRT $BGNE $INBX $MDCX $ONCS $MODV $VIR $REGN $SAGE $IOVA $TCRT $INDP $JNJ $NVS $SGEN $NVO
#DCVax #Immunotherapy #CellTherapy #PersonalizedMedicine #CancerVaccine #DendriticCells #BoosterStack #Flaskworks #BoschMatrix #ProjectOrbis #ModularManufacturing #CryogenicStorage #SI87 #CNPV #Biotech #Oncology #ImmuneSystem
1
1
2
984
$NWBO #DCVax ❄️ $MRK #Winterfell, the Long Night, and the Failed Trials
🏰 The Stronghold
Winterfell is the code name. WP50 is the building. Merck's three-floor facility at West Point, Pennsylvania, occupied early 2024, with sub-150°C cryogenic staging at the foundation, lyophilization paired with modular clean-room filling above, and no public program attribution. Sub-150°C exists for one reason: storing living cells. The architectural fingerprint specifically requires autologous cell therapy or equivalent living-cell modality. The lyophilization plus modular clean-room filling configuration is the signature of a lot factory, not a batch factory: many discrete patient-specific lots with chain-of-custody and release-testing as the rate-limiting bottlenecks. When Merck names its facilities (Wilmington for Keytruda biologics, Durham for vaccines, De Soto for Animal Health), it names them. WP50 carries no attribution. The selective silence is the anomaly. The stronghold is built before the war is declared.
The Long Night and the Army of the Dead
The metaphor extends through the entire combat ecology. In cancer immunology, the term cold tumor names a microenvironment with minimal T cell infiltration, suppressed dendritic cell function, and IL-6 to STAT3 to IRF8 silencing of IL-12 production. Cold tumors are unresponsive to checkpoint inhibitors because there is no inflammatory infiltrate to release. Cold tumors are the immunologically frozen territory beyond the Wall: glioblastoma, pancreatic adenocarcinoma, ovarian carcinoma, colorectal, the broader DCVax-Direct sixteen-tumor-type pipeline. The territory where the dead reign and the living do not return.
The army of the dead is the precise immunological match for the patient's exhausted T cell pool and silenced dendritic cell compartment. Cells present in the tumor microenvironment but not delivering the licensed Type-1 polarization signal needed for tumor clearance. They look alive by surface markers and population counts; they are not functioning. The molecular equivalent of the wight: the form of a soldier without the cellular instruction layer that makes the soldier engage.
The Night King is the silencing axis itself. The defining capacity of the Night King is the conversion of the living into the dead. The biological mechanism that converts a functioning immune cell into an exhausted one is the IL-6 to STAT3 to IRF8 silencing axis at the bone marrow dendritic cell progenitor layer. Chronic IL-6 from the tumor microenvironment phosphorylates STAT3, which silences IRF8, which eliminates IL-12 production, which exhausts the T cells that would otherwise engage the tumor. The Night King is the silencing axis. The army of the dead is the exhausted T cell pool the silencing axis produces.
Conventional weapons do not work against the army of the dead. Sword and arrow shatter on White Walker armor. Dragonglass and Valyrian steel are the only weapons that kill White Walkers. The αDC1 chemistry is the dragonglass of the metaphor. The mRNA cancer vaccine architecture is the conventional weapon.
The mRNA Architecture: Delivery to a Dead Instruction Layer
V940 was announced by Merck and Moderna in October 2022, with Merck exercising the development option following the Phase 2b mRNA-4157-P201 readout in melanoma at approximately two hundred fifty million dollars. V940 is engineered as mRNA-encoded patient-specific neoantigens in lipid nanoparticles, designed to deliver up to thirty-four computationally predicted neoantigens to the patient's endogenous dendritic cells. The lipid nanoparticle delivers the mRNA cargo to the DCs. The DCs take up the mRNA, translate the encoded peptides, process them through MHC class I and class II pathways, and present the neoantigens for T cell recognition. Pembrolizumab releases the checkpoint brake on the resulting T cell response.
The architecture is structurally identical to BNT122, which Roche and BioNTech announced in June 2016. BNT122 entered combination clinical development with the anti-PD-L1 antibody atezolizumab in the BNT122-01 melanoma Phase II. In October 2022, the BNT122-01 trial reported modest signal but not the durable response rate the program leadership had positioned for. The two leading checkpoint franchise owners (Merck with Keytruda, Roche with atezolizumab and Tecentriq) both executed the personalized mRNA neoantigen plus checkpoint combination as the architectural extension of their respective franchises. Both bets are structurally identical and addressed by the same architectural failure mode.
V940 presupposes the patient's endogenous dendritic cell compartment is Signal 3 competent. The V940 architecture delivers neoantigen substrate to the instruction layer it assumes exists. In immunologically cold tumors, the instruction layer is silenced. The IL-6 to STAT3 to IRF8 axis has eliminated IL-12 production at the bone marrow DC progenitor compartment. The patient's DC takes up V940 mRNA, presents the encoded neoantigens on MHC class I and II, delivers Signals 1 and 2 to the naive CD8 T cell, but cannot deliver Signal 3 above the Carreno IL-12p70 binary threshold (Journal of Clinical Investigation, 2013, approximately ten picograms per million cells per twenty-four hours). The T cell that receives Signals 1 and 2 without licensed Signal 3 exits the priming event toward exhaustion rather than execution-grade cytotoxicity.
V940 cannot fix what V940 presupposes. A second immunotherapy stacked on top of a first that has already failed cannot restore an instruction substrate neither modality carries. The mRNA delivers more antigen to a DC that cannot deliver the cytokine context that converts antigen into durable response. Steel swung against the army of the dead.
The #INTerpath Six-Trial Pattern
Merck and Moderna advanced V940 through the INTerpath designator across six disclosed trials. The trial portfolio is the empirical test of the platform's reach across the cold-to-hot tumor spectrum. INTerpath-001: Phase 3 in adjuvant resected high-risk melanoma, fully enrolled, readout approximately September 2026. INTerpath-002: Phase 3 in adjuvant resected non-small-cell lung cancer. INTerpath-004: Phase 2 in renal cell carcinoma. INTerpath-005: Phase 2 in urothelial carcinoma. INTerpath-007: Phase 2 in cutaneous squamous cell carcinoma, terminated October 2025 after approximately forty-six patients enrolled, without Phase 3 expansion. INTerpath-009: Phase 3 in NSCLC in the post-neoadjuvant setting. Six trials. Three Phase 3. Two Phase 2. One terminated.
The trial pattern maps onto the spectrum of endogenous DC competence across solid tumor indications. Melanoma has the most preserved endogenous DC compartment in the published cancer immunology literature. Tumor-infiltrating dendritic cell density is relatively high, baseline IL-12 production from those cells is relatively preserved, and melanoma's foundational role as the lead indication for checkpoint inhibitors traces directly to its relatively hot immunological status. INTerpath-001 advances to Phase 3 confirmation. The biology supports the bet in the easiest indication.
NSCLC has a more silenced endogenous DC compartment than melanoma but less silenced than the harder indications. INTerpath-002 and INTerpath-009 advance to Phase 3 confirmation across the resected and post-neoadjuvant settings respectively. Renal cell and urothelial carcinomas carry intermediate endogenous DC competence. Tumor-infiltrating DC populations vary substantially by patient and by molecular subtype. INTerpath-004 and INTerpath-005 remain at Phase 2 signal-finding, indicating Merck is still searching for the dose-effect signal that would justify Phase 3 advancement in these indications. The pattern is not random.
Cutaneous squamous cell carcinoma carries a heavily silenced endogenous DC compartment characteristic of HPV-driven and UV-driven head and neck malignancies. The cumulative chronic immune dysregulation in chronic actinic damage and HPV-driven malignancy is exactly the context where the IL-6 to STAT3 to IRF8 silencing axis has reached the most advanced state. INTerpath-007 terminated. The cold was complete; the conventional weapon failed.
The trial portfolio is the map of where the cold has not yet reached, where the cold has partially reached, and where the cold is total. The pattern is the empirical signature of a platform whose efficacy declines as the endogenous DC instruction layer becomes more silenced.
#INTerpath-007 as Prospective Falsification
INTerpath-007 terminated October 2025 after approximately forty-six patients enrolled. The termination followed KEYNOTE-630, the standalone pembrolizumab Phase 3 in the same cutaneous SCC indication, which had established that the underlying checkpoint inhibitor backbone in the V940 plus pembrolizumab combination had already failed in the indication before the combination was tested. INTerpath-007 is the first prospective falsification of the personalized mRNA neoantigen vaccine plus checkpoint inhibitor combination hypothesis in an indication where the Signal 3 deficit applies maximally.
Two layers of falsification are recorded. KEYNOTE-630 falsifies pembrolizumab monotherapy in cutaneous SCC: checkpoint release alone does not produce durable response when the underlying T cell priming layer is exhausted. INTerpath-007 falsifies V940 plus pembrolizumab combination in cutaneous SCC: adding mRNA-delivered neoantigen substrate to the failed checkpoint backbone does not produce durable response either, because the dendritic cell instruction layer V940 presupposes is silenced. Two empirical falsifications. Same indication. Same underlying instruction layer deficit. Two conventional weapons; both shattered against the same White Walker.
INTerpath-001 in September 2026 is the bidirectional event. Both outcomes carry the same implication for the αDC1 platform. If INTerpath-001 succeeds in melanoma (the easiest indication), the combination paradigm is validated where the endogenous compartment is most preserved, and an αDC1 instruction-installation architecture becomes the mechanistically required complement to extend the combination paradigm into the harder indications where the endogenous compartment is more silenced. If INTerpath-001 fails, the Signal 3 deficit has manifested at Phase 3 in Merck's flagship cancer vaccine program, and αDC1 becomes the required correction at the level of empirical Phase 3 evidence.
The six-trial pattern empirically demonstrates the V940 architecture cannot fix what V940 presupposes. The platform's reach is bounded by the endogenous DC competence of the indication being addressed. The cold tumor indications are structurally excluded from the V940 architecture's reach. mRNA does not work on cold tumors. The empirical record is in the trial portfolio.
The Dragonglass: Why αDC1 Works Where mRNA Fails
Pawel Kalinski first characterized dendritic cell exhaustion as the canonical failure mode of the legacy DC vaccine field in 1999. PGE2-containing maturation cocktails produced DCs with high CD83 expression, high migration capacity, and zero residual IL-12 production capacity. The legacy field's central failure was the engineering decision to use PGE2 in the maturation chemistry. The manufacturing process itself was producing wights rather than soldiers. Kalinski and Mailliard published the engineered solution in 2004. The αDC1 maturation chemistry replaces PGE2 with a five-component cocktail (IFN-α, IFN-γ, TNF-α, poly-I:C, IL-1β, applied for less than four hours), producing dendritic cells secreting IL-12p70 at approximately one hundred-fold increased output relative to legacy protocols. The IL-12 output is durable through the priming engagement at the lymph node compartment rather than burned out at manufacturing release.
The αDC1 platform is structurally distinct from mRNA cancer vaccines at the most consequential layer. mRNA delivers antigen substrate TO the patient's endogenous dendritic cells. αDC1 REPLACES the patient's endogenous dendritic cells with functional ones manufactured ex vivo. Where mRNA presupposes the instruction layer, αDC1 installs the instruction layer. Where mRNA arrives at a broken substrate in cold tumors, αDC1 delivers the substrate itself. The patient's T cell pool receives Signal 3 IL-12 above the Carreno binary threshold and exits priming activated rather than exhausted.
The αDC1 platform also reverses the silencing axis at the production layer. Downstream IFN-γ from the activated T cell pool reverses STAT3-mediated IRF8 silencing at the bone marrow hematopoietic stem and progenitor cell compartment. Subsequent dendritic cell generations are produced from the corrected bone marrow at restored IL-12 capacity. The Long Night ends because the source of the dead is corrected at the production layer. The patient's own bone marrow becomes the manufacturing facility for the corrected cascade across multiple cell generations.
The Kalinski Roswell Continuation
Kalinski continued the αDC1 chemistry development at Roswell Park through three architectural extensions. The Chemokine Modulatory regimen combines rintatolimod, IFN-α2b, and celecoxib to reshape the tumor microenvironment chemokine gradient toward CXCR3 and CCR5 effector T cell recruitment and away from regulatory T cell migration. The TGF-β resistant DC variant addresses the desmoplastic tumor microenvironment that defeats conventional αDC1 cells at the Signal 3 layer through TGF-β-mediated DC suppression; pancreatic adenocarcinoma, hepatocellular carcinoma, and the broader desmoplastic solid tumor category sit inside the TGF-β resistant variant's mechanistic reach. The next-generation peptide panel architecture covers HER2 and HER3 overexpressing malignancies, including HER2-positive and triple-negative breast cancer, gastric cancer, and the broader HER2-amplified solid tumor population. Three extensions. Three failure modes addressed beyond the base αDC1 chemistry. Three structural reaches into specific cold-tumor microenvironments where the base chemistry alone is insufficient.
The Three-Patent Perimeter
The patent record consolidates the full thirty-year Kalinski body of work into NWBio's corporate perimeter. US12059434B2 (Short-term Activated DC1s and Methods) is granted, jointly assigned to Health Research Inc. at Roswell Park and the University of Pittsburgh, and exclusively licensed to NWBio. It is the foundational manufacturing patent for any NWBio αDC1 product including DCVax-L, DCVax-Direct, and DCVax-T.
US20240299544A1 (Cancer Therapies Comprising Peptide Loaded CXCR3 and CCR5 Inducing Dendritic Cells and Chemokine Modulatory Agents) is pending at the USPTO, co-invented by Kalinski and Czerniecki, within the Roswell exclusive license closed June 12, 2024. The application claims the complete αDC1 maturation protocol combined with the HER2 and HER3 peptide panel, the Chemokine Modulatory regimen (rintatolimod plus IFN-α2b plus celecoxib), checkpoint inhibitor combinations including pembrolizumab, trastuzumab plus pertuzumab combinations, and adoptive T cell therapy through ex vivo αDC1 priming.
WO2025096694A1 covers the TGF-β resistant DC variant extending the platform mechanistic reach into pancreatic adenocarcinoma, hepatocellular carcinoma, and the broader desmoplastic solid tumor category where the TGF-β concentration at the tumor microenvironment exceeds the suppression threshold for standard αDC1 chemistry. The three patents together foreclose any company from sequencing dendritic cell vaccine plus checkpoint inhibitor across the global checkpoint franchise without licensing from NWBio. The dragonglass mine is consolidated under a single deed.
The Poly-ICLC Patent Bridge
Merck holds patent WO2022031314A2 covering scalable production of polyribonucleotides of controlled size. The synthesis chemistry applies directly to poly-ICLC (Hiltonol), the TLR3 agonist component disclosed by Dr. Marnix Bosch at the New York Academy of Sciences Frontiers in Cancer Immunotherapy conference on June 16, 2025 as part of the next-generation DCVax DC1 maturation supercharging cocktail. Poly-ICLC manufacturing requires lyophilization. Winterfell's second-floor lyophilization infrastructure is architecturally capable of producing the TLR3 adjuvant component of the next-generation αDC1 maturation chemistry under Merck's own manufacturing patent. The dragonglass forge inside the stronghold.
The manufacturing-IP plus infrastructure plus supercharging-component convergence is the manufacturing-bridge layer between Merck's adjuvant production capability and the NWBio αDC1 chemistry. Merck does not need to license poly-ICLC manufacturing from a third party. Merck owns the patent. The infrastructure to use the patent exists at the same site configured for living-cell modality storage and lot-factory filling.
The November 2025 Hire
On November 16, 2025, Merck posted a vaccinology postdoctoral fellow position at West Point, requisition R371970, filled by early 2026. The preferred qualifications enumerate the precise competency stack for evaluating the αDC1 plus supercharging adjuvant architecture preclinically: dendritic cell co-culture systems involving B and T cells, antigen presentation assays, BCR repertoire sequencing, ELISA, ELISPOT, high-parameter flow cytometry, cell sorting, in vitro restimulation assays, adjuvant evaluation focus. The position represented the first appearance of "dendritic cell" in a Merck West Point vaccinology posting per community-research review of historical postings at the site.
The hire is the Merck-side mirror of the NWBio operator-team pre-positioning pattern. A pharmaceutical company configuring a manufacturing facility for autologous cell therapy and hiring a dendritic cell vaccinology research fellow at the same location at approximately the same time is documenting the technology evaluation activity that necessarily precedes a partnership transaction. The steward is installed at the stronghold ahead of the announcement.
The #Keytruda 2028 LOE Clock
Keytruda faces composition-of-matter patent expiration approximately 2028 to 2030 across major global markets, with the US primary patent expiring 2028. Keytruda revenue exceeded thirty billion dollars in fiscal 2025, making it the largest single-product pharmaceutical franchise in history at peak. The replacement franchise architecture required to defend the checkpoint position into the post-2028 horizon must be operational by approximately 2027 to be commercially material at the LOE inflection. This is the long winter the Winterfell stronghold is prepared for.
#V940 plus Keytruda addresses the post-LOE franchise question in indications where the endogenous DC compartment is relatively competent. The growth indications Merck needs to enter to defend franchise scale are precisely the indications where V940 fails because the endogenous instruction layer is silenced: glioblastoma, pancreatic, colorectal, ovarian, the broader DCVax-Direct sixteen-tumor-type pipeline. The only published architecture addressing the silenced instruction layer is the integrated αDC1 platform that installs IL-12-competent dendritic cells from outside the patient's failed cascade. Merck cannot reach the cold tumor indications V940 alone cannot reach without licensing the DCVax architecture. The combination patent forecloses the alternative pathway. The 2028 LOE clock makes the partnership transaction timing structural rather than discretionary. Merck cannot defend the franchise into the long winter with steel alone.
Annalisa Jenkins as Integration-Node Operator
Annalisa Jenkins is the operator whose career signature is partnership architecture. She holds the M.B.B.S. and the Fellowship of the Royal College of Physicians, with Royal Navy medical officer service during the Gulf Conflict reaching surgeon lieutenant commander. She joined Bristol Myers Squibb and remained fifteen years, rising to Senior Vice President and Head of Global Medical Affairs, then served as Executive Vice President and Head of Global R&D at the biopharmaceutical division of Merck Serono with operational responsibility for more than sixty development programs. She served as President and CEO of Dimension Therapeutics, taking the company public on Nasdaq under DMTX and selling to Ultragenyx in November 2017 for approximately one hundred fifty-two million dollars cash at six dollars per share. Dimension was founded in 2014 from Harvard and Howard Hughes Medical Institute AAV gene therapy intellectual property; the arc is the closest career analog to what the NWBio platform requires: academic IP licensed into a corporate vehicle, translated through manufacturing development, exited through strategic acquisition.
She holds FDA Science Board membership at the institutional governance layer. She holds the Officer of the Order of the British Empire awarded in the King's 2026 New Year Honours announced December 29, 2025, conferred four months before the NWBio appointment. The UK life sciences governance portfolio includes The King's Fund, Genomics England, Protas, and the Institute of Directors launch with Freeman. She served four and one-half years at Ori Biotech before her April 1, 2026 elevation to Ori Chair. April 30, 2026: NWBio announces Jenkins as Strategic Adviser. Eight days separate the April 22, 2026 MHRA action on UK MIA 54923 commercial cell therapy manufacturing licence and the Jenkins appointment. Three dates within a thirty-day window. The credential stack is what executing a transatlantic pharmaceutical partnership operationalizing the αDC1 platform across MHRA, FDA, NHS, and US commercial deployment infrastructure requires.
The Convergence at the Stronghold
The convergence resolves at one location through five layers. Winterfell at the manufacturing layer. The Kalinski thirty-year body of work at the chemistry and intellectual property layer. The V940 INTerpath six-trial program at the empirical clinical evidence layer, with INTerpath-007 as the first prospective falsification and INTerpath-001 in September 2026 as the bidirectional event. The Keytruda 2028 loss of exclusivity at the partnership-transaction forcing-function layer. Annalisa Jenkins at the operator-execution layer.
The five layers converge because the biology routes them. The αDC1 chemistry is the only published architecture that installs the Signal 3 IL-12 cytokine context the V940 program demonstrated is missing across the spectrum of endogenous DC competence. The Pittsburgh and Roswell intellectual property perimeter forecloses the alternative pathway. The Keytruda 2028 loss of exclusivity establishes the timing. The Jenkins credential stack establishes the operator. The Winterfell stronghold establishes the manufacturing capability.
Winter is coming for the existing checkpoint franchise architecture. The army of the dead is at the gates: glioblastoma, pancreatic, ovarian, colorectal, the broader cold tumor portfolio that the silencing axis has converted from territory the patient's immune system should defend into territory the army of the dead now occupies. Conventional steel has failed in the coldest indications; INTerpath-007 is the empirical record. #KEYNOTE-630 is the empirical record one layer beneath. Two falsifications. Same indication. Same silenced instruction layer. The mRNA cancer vaccine plus checkpoint inhibitor combination architecture is bounded above by the endogenous DC competence of the indication being addressed, and the bound has now been documented at the cold end of the spectrum.
#Winterfell is the stronghold prepared at the manufacturing layer. Dragonglass is the αDC1 chemistry the stronghold will produce. The Night King is the IL-6 to STAT3 to IRF8 silencing axis. The αDC1 platform reverses the silencing at the production layer and ends the Long Night for the patient's bone marrow. The trigger event is the MHRA MAA decision. The biology decides.
2
9
49
4,173
May 22
Personalized neoantigen vaccines continue to gain momentum in thoracic oncology.
The phase III INTerpath-002 study is evaluating V940 (mRNA-4157) pembrolizumab in resected stage II–IIIB NSCLC.
The rationale stems from:
• early antitumor activity seen in KEYNOTE-603 across solid tumors including NSCLC
• and encouraging melanoma data from KEYNOTE-942, where V940 pembrolizumab improved:
• recurrence-free survival (HR 0.56)
• distant metastasis-free survival (HR 0.35)
The concept is compelling; using each patient’s unique neoantigen profile to generate a personalized immune response.
Now the key question:
Can this strategy meaningfully improve cure rates in resected NSCLC?
A fascinating space to watch. #ASCO26 #LCSM #melanoma @UVMcancercenter @ASCO
1
8
962
May 21
ASCO abstract for $MRK $MRNA Ph2b personalized cancer vaccine for melanoma patients. RFS HR=0.51, OS HR=0.47
With INTerpath-001 Ph3 trial 7x the size of this Ph2b, this is highly likely to readout positive later this year ($MRK management guided ~Sep 2026)
$PSNL is the exclusive lab who sequenced these tumors and identified/predicted immunogenic antigens for personalized vaccine development
Annual number of resectable high-risk Stage IIB-IV Melanoma
- US: 25,000
- Ex-US: 50,000
1
11
71
23,915
Revealed: KPMG UK, the big four accountancy firm, is trying to recruit a heavyweight team of restructuring professionals to spearhead a return to the sector five years after it offloaded the division which became Interpath Advisory for about £350m. news.sky.com/story/mark-klei…
1
1
7
11,072
7yo KAMARAN (Kerryn & Peter Manning) continues his rich vein of form winning the INTERPATH GLOBAL TROT @Bdtc150 in stirring fashion by 11m Congrats the BD Crilly LC Crilly JV Gritty, KC Covington
1
4
346
Apr 16
Baréma Bocoum (Interpath) : « J'ai vu des entreprises mourir parce qu'on ne disait pas la vérité au chef » l.latribune.fr/qCn
455
Movers & Shakers: IndiGo, Interpath, Sherry Fitzgerald, Lisney, Fieldfisher businesspost.ie/companies/mo…
413
Interpath Ireland appoints Kirstie O’Flanagan as managing director businesspost.ie/article/inte…
361